CRISIL ESG Ratings & Analytics Limited, a SEBI-registered Category-I ESG Ratings Provider, has independently assigned an ESG Rating of 64 to the Company. This rating falls under the "Strong" category and represents a significant improvement from the Company's previous ESG Rating of 57, which was classified under the "Adequate" category.
The Company's Core ESG Rating has also shown substantial improvement, rising to 71 from the previous rating of 60.
It is specifically noted that the Company did not engage CRISIL ESG Ratings for obtaining these ESG Ratings. The ratings were independently prepared by CRISIL based on the Company's disclosures for FY2026 and other publicly available information.
The disclosure has been made available on the Company's website at www.mankindpharma.com.